Retrospective evaluation of LCP‐tacrolimus (Envarsus XR) dosing in de novo kidney transplant
Clinical Transplantation · 2023
DOI: 10.1111/ctr.15082 ↗At a glance
Journal article in Clinical Transplantation, 2023. Written by Mohammed Alzahrani and 6 co-authors. Institution: Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois, USA. Major MEDLINE topics: Tacrolimus, Kidney Transplantation. Cited 1 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Veloxis Pharmaceuticals.
Abstract (original language)
Introduction
Tacrolimus is known to exhibit significant inter‐ and intra‐patient pharmacokinetic (PK) and pharmacodynamic (PD) variability regarding therapeutic response. LCP‐tacrolimus (LCPT—Envarsus XR) was approved in 2018 for use as a de novo immunosuppressive agent in kidney transplants, but there is limited evidence to guide de novo dosing of LCPT in patients with obesity. The primary objective of this study was to evaluate the impact of different calculated weight‐based de novo LCPT dosing on early transplant outcomes.
Methods
This was a retrospective study of patients with obesity (BMI ≥ 30 kg/m 2 ) who received a kidney transplant at the University of Illinois Hospital and Health System (UIH), between March 2019 and March 2021. Subjects were included if were age 18 years or older and received de novo LCPT throughout index hospitalization. The primary endpoint of this study was to compare correlations between the first tacrolimus trough level and dosing weight strategy (e.g., TBW, AdjBW, IBW).
Results
There was a statistically significant, though modest, correlation between all three dosing strategies and the first tacrolimus trough level (TBW correlation coefficient = .431, p < .001; AdjBW correlation coefficient = .455, p < .001; IBW correlation coefficient = .465; p < .001). In regression modeling for supratherapeutic levels each additional .01 mg/kg increase in dose by TBW, AdjBW, and IBW increased the odds of a supratherapeutic level by 1.46, 1.34, and 1.24, respectively ( p < .001).
Conclusions
The use of LCPT in kidney transplant recipients with obesity dosed using TBW demonstrated the strongest correlation with initial supratherapeutic tacrolimus levels. Larger prospective studies are needed to investigate the further impact of body weight on dosing regimens in the obese population.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois, USA.
- Department of Surgery, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
ORCID profiles: Rachel M Belcher, Jamie Benken, Scott T Benken
Funding
- Veloxis Pharmaceuticals
Cite
APA
Alzahrani, M., Belcher, R. M., Benken, J., Valdepenas, B., Di Cocco, P., Kajavathanan, M., & Benken, S. T. (2023). Retrospective evaluation of LCP‐tacrolimus (Envarsus XR) dosing in de novo kidney transplant. Clinical Transplantation. https://doi.org/10.1111/ctr.15082
Vancouver
Alzahrani M, Belcher RM, Benken J, Valdepenas B, Di Cocco P, Kajavathanan M, et al. Retrospective evaluation of LCP‐tacrolimus (Envarsus XR) dosing in de novo kidney transplant. Clinical Transplantation. 2023. doi:10.1111/ctr.15082
BibTeX
@article{Alzahrani2023,
author = {Alzahrani, Mohammed and Belcher, Rachel M and Benken, Jamie and Valdepenas, Benito and Di Cocco, Pierpaolo and Kajavathanan, Mathula and Benken, Scott T},
title = {Retrospective evaluation of LCP‐tacrolimus (Envarsus XR) dosing in de novo kidney transplant},
journal = {Clinical Transplantation},
year = {2023},
doi = {10.1111/ctr.15082}
}
EUVIMED